[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nstemi---non-st-segment-elevation-mi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nstemi---non-st-segment-elevation-mi":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,90,116,146,183,214,242],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100545664","diagnostic-performance-of-artificial-intelligence-algorithms-in-prediction-of-acute-coronary-syndrome-based-on-white-blood-cell-properties-100545664",false,"NCT06384846","Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties","Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties (AI-ACS Trial)","Inclusion Criteria:\n\nGeneral inclusion criteria:\n\n* Male or female, aged 18 years or above.\n* Participant is willing and able to give informed consent for participation in the study.\n* Collection of WBC and hs-cTn data must be possible.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled, where applicable.\n\nCase cohort:\n\n* Suspicion of STEMI or NSTE-ACS according to current ESC guidelines.\n* Coronary angiography must have been performed within 72 hours after initial suspicion of ACS.\n* For patients qualifying for observation according to ESC guidelines, coronary angiography is not mandatory and time limits do not apply.\n* Confirmation of STEMI or NSTE-ACS by identification of a culprit lesion using coronary angiography; identical evaluation results by review board required.\n* For observation patients without coronary angiography, final discharge diagnosis is used to decide about the presence or absence of NSTEMI and\u002For ACS.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nControl cohort:\n\n* Suspicion of STEMI or NSTE-ACS according to current ESC guidelines.\n* Coronary angiography must have been performed within 72 hours after initial suspicion of ACS.\n* No identification of a culprit lesion compatible with diagnosis of STEMI or NSTE-ACS during coronary angiography; identical evaluation results by review board required.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nSupplementary cohort:\n\n* Subject presents without chest pain or with stable angina pectoris.\n* No indication for revascularization during coronary angiography; identical evaluation results by review board required.\n* Exclusion of elevated hs-cTn.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n* Between initial blood sampling to collect WBC data and coronary angiography, the subject must not develop suspicion of ACS.\n\nRule-out cohort:\n\n* Suspicion of NSTE-ACS and NSTEMI rule-out according to current ESC guidelines, i.e. very low initial hs-cTn value, or low initial hs-cTn value and no significant 1-hour\u002F2-hour change in hs-cTn value.\n* No coronary angiography within 72 hours.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nAll-comer cohort:\n\n* Subject presents to the emergency department with suspected ACS.\n* Clinical assessments, ECG, and measurements of hs-cTn, single or serial measurement, must be conducted according to ESC guidelines.\n* Collection of WBC data must be performed at initial blood withdrawal after admission to the emergency department.\n* Review board evaluations must confirm the presence or absence of a culprit lesion if coronary angiography was performed, as outlined for the case and control cohorts.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Subject refuses informed consent.\n* Collection of WBC and hs-cTn data is not possible.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data cannot be fulfilled.\n* Suspicion of ACS occurs in subjects with no or stable angina pectoris any time between initial blood sampling and start of coronary angiography.",true,"ALL","18 Years",{"count":20,"type":21},3350,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing. The main questions the study aims to answer are:\n\n* Can AI algorithms based on white blood cell (WBC) data predict or exclude ACS in subjects with suspected ACS?\n* Can erythrocyte (EC) and\u002For thrombocyte (TC) data, where available, improve or complement WBC-based AI prediction of ACS?\n* How does the diagnostic performance of the AI algorithms compare with high-sensitivity cardiac troponin (hs-cTn), and can the combination of AI algorithms and hs-cTn improve diagnostic performance?\n\nParticipants will undergo clinical assessment and blood testing as part of usual clinical care. Their previously generated clinical information, hematology data, and hs-cTn results will be used to train and test the AI algorithms. Participation in the study does not determine the indication for coronary angiography or treatment, and no additional study-specific treatments are performed.",[25,26,27,28,29],"Acute Coronary Syndrome","Angina Pectoris","NSTEMI - Non-ST Segment Elevation MI","STEMI - ST Elevation Myocardial Infarction","Unstable Angina (UA)",[31,32,33,34,35,36,37],"Artificial Intelligence","AI","hematology analyzer","ACS","white blood cell","Troponin","Machine learning","RECRUITING","2026-06-21",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":42},"2024-02-01",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"RobotDreams GmbH","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":50},"100612716","phase-3-aspirin-free-strategy-with-ticagrelor-in-patients-with-a-myocardial-infarction-treated-medically-alone-100612716","NCT07257198","Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)","PANTHEON","Inclusion criteria:\n\n* Age ≥18 years;\n* Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;\n* Coronary angiogram performed;\n* Planned for medical management alone, without revascularization;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥12 months.\n\nExclusion criteria:\n\n* Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;\n* Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;\n* Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);\n* Confirmed or suspected spontaneous coronary artery dissection;\n* Concomitant indication for chronic oral anticoagulant;\n* Concomitant non-coronary indication for dual antiplatelet therapy;\n* Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;\n* Previous hospitalization for MI, PCI, or CABG within 12 months;\n* Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;\n* Unsuitability for either randomization treatment, based on the judgement of the treating physician",{"count":60,"type":21},2570,"INTERVENTIONAL",[63],"PHASE3","In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.",[27,66,67],"STEMI (ST Elevation MI)","Myocardial Infarction",[69,70,71,72,73,74,75,76,77,78,79],"Dual antiplatelet therapy","NSTEMI","medical treatment","STEMI","aspirin","ticagrelor","bleeding","ischemic events","randomized trial","pragmatic trial","randomized controlled trial","2026-03-08",{"date":82,"type":42},"2026-03-10",{"date":84,"type":42},"2026-03-03",{"date":86,"type":21},"2031-01-01",{"name":88,"class":89},"Montreal Heart Institute","OTHER",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":61,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100619319","efficacy-of-immediate-versus-staged-complete-revascularization-in-patients-with-nste-acs-and-multivessel-disease-future-ii-100619319","NCT07343076","Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)","Inclusion Criteria:\n\n1. Age: 18 years or older.\n2. Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.\n3. PCI within 72 hours of diagnosis.\n4. Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.\n5. Sign an informed consent form before participating in the study.\n\nExclusion Criteria:\n\n1. Have received thrombolytic treatment.\n2. Cardiogenic shock or SBP\\\u003C 90 mmHg.\n3. Patients in whom the culprit vessel cannot be clearly identified.\n4. Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation\u002Flaser.\n5. Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).\n6. Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.\n7. Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \\\u003C30ml\u002Fmin), hepatic insufficiency, thrombocytopenia (≤50\\*109\u002FL).\n8. Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.\n9. Not suitable for clinical study:\n\n   1. Have enrolled in the other clinical studies that may affect the outcome assessment of this study.\n   2. Pregnant and lactating women.\n   3. Known allergy to the drugs that may be used in the study.\n   4. Unable to comply with the trial protocol or follow-up requirements; or the investigator believes that participation in the trial may put the patient at greater risk.",{"count":97,"type":21},1904,[99],"NA","This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD).\n\nNSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form:\n\nIntervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing).\n\nControl group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.",[70,27,102,103],"Non-ST-elevation Acute Coronary Syndrome","NSTE-ACS (NSTEMI and UA)",[70,105],"FUTURE II","NOT_YET_RECRUITING","2026-01-28",{"date":109,"type":42},"2026-01-30",{"date":111,"type":21},"2026-02-28",{"date":113,"type":21},"2031-02-28",{"name":115,"class":89},"RenJi Hospital",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":61,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100621308","advanced-nanotherapies-dual-api-dcb-to-treat-de-novo-and-isr-lesions-in-patients-with-symptomatic-coronary-artery-disease-100621308","NCT07368933","Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease","ADVANCEd NanoTherapies SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter to Treat Coronary In-stent Restenosis (ISR) and de Novo Lesions","ADVANCE-DUO","Inclusion Criteria:\n\n1. ≥18 years or minimum legal age as required by local regulations.\n2. Documented stable or unstable angina, positive functional test, or non -ST elevation myocardial infarction which, in the judgment of the operator, is attributable to disease in coronary vessel or in-stent restenosis, and the patient is deemed an appropriate candidate for PCI in accordance with the applicable guidelines on percutaneous coronary intervention.\n\n   Note: participants with NSTEMI must have enzymes that are trending down or are within normal limits prior to enrollment.\n3. Life expectancy \\>1 year in the Investigator's opinion.\n4. Participant is willing and able to cooperate with study procedures and follow-up evaluations.\n5. Treatment of only one target lesion required\n\n   1. Tandem lesions treated by a single DCB will be considered one target lesion.\n   2. Up to one de novo lesion in a separate vessel may be treated per standard of care at the procedure. Non-target lesions must be successfully treated under the same criteria of the target lesion, before treating the target lesion.\n6. Target lesion must be ≤36 mm in length.\n7. Target lesion must have a stenosis ≥ 50% and \\\u003C 100%.\n8. Target lesion must have a visually estimated reference vessel diameter of:\n\n   1. ISR lesions: 2.0 to 4.0 mm in diameter (inclusive)\n   2. de novo lesions: 2.0 to \\\u003C3.0 mm in diameter\n9. ISR lesions only: target lesion must be within a previous BMS or DES that does not extend \\>5.0 mm beyond the proximal or distal edge.\n\nExclusion Criteria:\n\n1. Participant is pregnant, or breastfeeding. Note: Participant of childbearing potential must have a negative pregnancy test within 7 days before procedure.\n2. Known hypersensitivity or contraindication to antiplatelet medications (e.g., aspirin; heparin; prasugrel); or a sensitivity to contrast media which cannot be adequately pre-medicated.\n3. History of an allergic reaction or significant sensitivity to paclitaxel, sirolimus, or any other analogue or derivative.\n4. Platelet count \\\u003C 100,000 cells\u002Fmm³ (i.e., 100 x 109 \u002FL) or \\> 700,000 cells\u002Fmm³ (i.e., 700 x 10 9 \u002FL), or a white blood cell (WBC) count \\\u003C 3,000 cells\u002Fmm³ within 7 days prior to procedure.\n5. Renal insufficiency (Serum creatinine level \\> 2.5 mg\u002Fdl (i.e., 221 μmol\u002FL) within 7 days prior to procedure) or failure (dialysis dependent).\n6. Evidence of an acute MI within 72 hours of the procedure Note: participants with NSTEMI are allowed, provided enzymes are trending down or are within normal limits prior to enrollment.\n7. Previous PCI of the target vessel within 6 months prior to procedure.\n8. History of a stroke or transient ischemic attack (TIA) within the prior 3 months to procedure (any prior stroke or TIA, if prasugrel is used).\n9. Planned PCI of any vessel within 30 days post-procedure and\u002For planned PCI of the target vessel within 12 months post-procedure.\n10. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months to procedure.\n11. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.\n12. Documented left ventricular ejection fraction (LVEF) \\\u003C30% at the most recent evaluation, within the prior 3 months to procedure.\n13. Planned surgery that would cause interruption in recommended DAPT duration per current guidelines.\n14. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS, or other coronary artery imaging procedures.\n15. The following criteria related to previous treatments applies based on the type of lesion treated. The participant is excluded in the following circumstances:\n\n    1. ISR lesions: If single-layer ISR, any previous treatment of the target vessel for restenosis. If double- layer ISR, any treatment of the double-layer ISR.\n    2. de novo lesions: any previous treatment of the target lesion.\n16. Planned PCI of three vessel disease during procedure.\n17. Planned treatment of more than one target vessel. Tandem lesions that can be treated by a single DCB are permissible.\n18. Target lesion requires treatment with atherectomy, laser, or thrombectomy procedure.\n19. Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate.\n20. Target vessel has evidence of thrombus.\n21. Target vessel is excessively tortuous, defined as more than one bend \\>90° to reach target lesion.\n22. Target lesion has any of following characteristics:\n\n    1. Lesion location is unprotected in left main coronary artery, internal mammary artery, aorto-ostial, bypass grafts, ostial lesions or within 5 mm of the origin of the left anterior descending or left circumflex.\n    2. Involves a side branch \\>2.0 mm in diameter.\n    3. Is severely calcified.\n23. The following criteria based on number and type of lesions:\n\n    1. ISR and de novo lesions: target lesion is in the same vessel with a de novo lesion requiring treatment.\n    2. ISR lesions: planned treatment of a ≥3 layer ISR lesion.",{"count":125,"type":21},30,[99],"The study objectives are:\n\n1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease.\n2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \\\u003C3.00 mm in diameter in patients with symptomatic coronary artery disease.",[129,130,131,27],"Angina (Stable)","CAD - Coronary Artery Disease","Unstable Angina",[133,134,135],"DCB","Drug Coated Balloon","Coronary Artery Disease","2026-01-23",{"date":138,"type":42},"2026-01-27",{"date":140,"type":42},"2025-12-15",{"date":142,"type":21},"2029-01",{"name":144,"class":49},"Advanced NanoTherapies",3,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":61,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":50},"100592685","breaking-fasts-ahead-of-cardiac-caths-100592685","NCT06996639","Breaking Fasts Ahead of Cardiac Caths","Breaking Fasts Ahead of Cardiac Caths: an Open Label Non-Blinded RCT (BACON-RCT)","BACON-RCT","Inclusion Criteria:\n\n* All scheduled urgent inpatient non-high risk cardiac catheterizations for worsening angina (cardiac chest pain or anginal equivalent), unstable angina, or non-high risk NSTEMI-NSTEMI's with GRACE score \\\u003C140 points) utilizing proceduralist guided sedation\n\nExclusion Criteria:\n\n* High risk NSTEMI's defined as NSTEMI's with a GRACE score \\>140 points\n* Hemodynamic instability (\\\u003CSBP 90)\n* Unstable arrythmias\n* Chest pain refractory to nitroglycerin drip\n* New ejection fraction less than 25%\n* Evidence of severe decompensated heart failure on presentation requiring BiPAP or mechanical intubation\n* Inability to consent\n* Patients \\\u003C18 years old\n* Pregnant patients\n* Need for general anesthesia\n* Acute hypoxic respiratory failure requiring \\>6L Nasal Cannula Supplementation, BiPAP, or invasive ventilation\n* Emergent interventions: STEMI\u002Fhigh risk NSTEMI\n* Need for mechanical circulatory support-ECMO, Impella or intra-aortic balloon pump",{"count":155,"type":21},400,[99],"The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications.\n\nThe study will answer:\n\n* Does eating and drinking before the procedure improve patient comfort?\n* Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc?\n\nParticipants will be randomly assigned to either:\n\n* A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or\n* A no-fasting group (able to eat and drink as usual).\n\nPatients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.",[159,29,27],"Stable Angina (SA)",[161,162,163,34,164,131,165,166,70,25,167,168,169,170,171,172,173],"Fasting","NPO","Cardiac Catheterization","Angina","Worsening Angina","Low Risk NSTEMI","Urgent Cardiac Catheterization","Patient satisfaction","Periprocedural care","Non-fasting","Safety outcomes","Pre-procedural protocol","Survey-based research","2025-12-08",{"date":176,"type":42},"2025-12-16",{"date":178,"type":42},"2025-10-13",{"date":180,"type":21},"2026-07",{"name":182,"class":89},"University of South Florida",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":192,"targetDuration":194,"studyType":22,"phases":4,"briefSummary":195,"conditions":196,"keywords":201,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":50},"100594996","tirana-acs-a-prospective-registry-study-for-the-targeted-investigation-of-residual-inflammation-after-non-st-st-elevation-acute-coronary-syndrome-100594996","NCT07026708","TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome","Target Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY","TIRANA (ACS)","Inclusion Criteria:\n\n\\- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or\u002Fand the cardiology intensive care unit with a diagnosis of ACS\n\nExclusion Criteria:\n\n* Patients presenting to the cardiology department or\u002Fand the cardiology intensive care unit with diagnoses other than ACS and\u002For UA. Patients who died before undergoing PCI and those who did not provide a contact number.","85 Years",{"count":193,"type":21},1600,"2 Years","This prospective observational study aims to evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) as a predictor of mortality in patients following an episode of Acute Coronary Syndrome (ACS). Despite advancements in interventional cardiology and medical therapy, mortality remains significant in post-ACS patients, and early risk stratification is essential for optimizing outcomes.\n\nRecent studies have suggested that systemic inflammatory markers, such as NLR, are associated with adverse cardiovascular events. It is an easily obtainable and cost-effective laboratory parameter derived from a routine complete blood count. However, its value as an independent predictor of mortality post-ACS has not yet been fully established in our population.\n\nThe study will include patients aged, admitted with a confirmed diagnosis of ACS (STEMI or Non-STEMI) and treated with percutaneous coronary intervention (PCI). NLR values will be measured from the first blood draw upon hospital admission, 24 and 48 hours post PCI. Patients will be followed up for up to 6 months after discharge through telephone interviews .\n\nFirst, primary outcomes of the study will be the association between NLR values and mortality (all cause mortality and cardiovascular mortality), MACE (MACE was defined as the composite of all-cause mortality, cardiac death, unplanned revascularization, non-fatal myocardial infarction that was attributable and not related to stent failure or unplanned revascularization not related to stent failure) within 6 months post-ACS.\n\nSecondary outcomes will include:\n\n1. Differences in mean NLR between STEMI and NSTEMI patients.\n2. Association between elevated NLR and the presence of multivessel coronary artery disease on angiography.\n3. Correlation of NLR with other biomarkers, including the platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and maximum troponin levels (as an indicator of myocardial infarction size)\n\nThis study aims to contribute to the identification of easily accessible and cost-efficient biomarkers that can aid clinicians in early risk stratification of ACS survivors. A strong correlation between high NLR values and increased post-discharge mortality would suggest that inflammation plays a key role in patient prognosis and could potentially influence post-ACS management strategies.",[197,198,199,200,27,72],"ACS (Acute Coronary Syndrome)","Myocardial Infarction (MI)","Myocardial Inflammation","Inflammation Biomarkers",[202,203,204,25],"Residual inflammation","Myocardial infarction","Percutaneous Coronary Intervention","2025-09-27",{"date":207,"type":42},"2025-09-30",{"date":209,"type":42},"2024-11-01",{"date":211,"type":21},"2027-06-01",{"name":213,"class":89},"University Hospital Centre Mother Teresa",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":50},"100587392","machine-learning-to-boost-the-early-diagnosis-of-acute-cardiovascular-conditions-100587392","NCT06927791","MAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions","MALBEC","Inclusion Criteria:\n\n• Acute cardiovascular disease (ACVD)\n\nExclusion Criteria\n\n* age \\\u003C 18 years old\n* patients presenting in cardiogenic shock\n* chronic terminal kidney failure requiring dialysis",{"count":222,"type":21},200000,"The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute life-threatening cardiovascular conditions in emergency department (ED) patients with chest pain or dyspnea with the ultimate goal of Improved diagnostic accuracy, faster patient management, and reduced medical errors.",[225,226,27],"Acute Cardiovascular Disease","ST-segment Elevation Myocardial Infarction (STEMI)",[228,229,230,231,31,232],"Machine Learning","Clinical Decision Support Tool","Cardiac Biomarkers","Deep Transfer Learning (DTL)","Acute cardiovascular conditions","2025-04-07",{"date":235,"type":42},"2025-04-15",{"date":237,"type":42},"2024-04-01",{"date":239,"type":21},"2027-03",{"name":241,"class":89},"University Hospital, Basel, Switzerland",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":61,"phases":252,"briefSummary":254,"conditions":255,"keywords":262,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100396044","phase-4-what-is-the-optimal-antithrombotic-strategy-in-patients-with-atrial-fibrillation-undergoing-pci-100396044","NCT04436978","What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Having Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention?","WOEST-3","Inclusion Criteria:\n\n1. Patients ≥ 18 years\n2. Undergoing successful PCI (either ACS or elective PCI)\n3. History of or newly diagnosed (\\\u003C72 hours after PCI\u002FACS) atrial fibrillation or flutter with a long-term (≥ 1 year) indication for OAC\n\nExclusion Criteria:\n\n1. Contra indication to edoxaban, aspirin or all P2Y12 inhibitors\n2. Current indication for OAC besides atrial fibrillation\u002Fflutter (e.g. venous thromboembolism)\n3. \\\u003C12 months after any stroke\n4. CHADSVASc score ≥7\n5. Moderate to severe mitral valve stenosis (AVA ≤1.5 cm2)\n6. Mechanical heart valve prosthesis\n7. Intracardiac thrombus or apical aneurysm requiring OAC\n8. Poor LV function (LVEF \\\u003C30%) with proven slow-flow\n9. History of intracranial haemorrhage\n10. Active bleeding on randomization\n11. History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding, unless the causative factor has been permanently resolved\n12. Recent (\\\u003C1 month) gastrointestinal haemorrhage, unless the causative factor has been permanently resolved.\n13. Known coagulopathy\n14. Severe anaemia requiring blood transfusion or thrombocytopenia \\\u003C50 × 109\u002FL\n15. BMI \\>40 or bariatric surgery\n16. Kidney failure (eGFR \\\u003C15)\n17. Active liver disease (ALT, ASP, AP \\>3x ULN or active hepatitis A, B or C)\n18. Active malignancy excluding non-melanoma skin cancer\n19. Life expectancy \\\u003C1 year\n20. Pregnancy or breast-feeding women",{"count":251,"type":21},2000,[253],"PHASE4","The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown. AF patients are treated with oral anticoagulation (OAC) to prevent ischemic stroke and systemic embolism and patients undergoing percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy (DAPT), i.e. aspirin plus P2Y12 inhibitor, to prevent stent thrombosis (ST) and myocardial infarction (MI). Patients with AF undergoing PCI were traditionally treated with triple antithrombotic therapy (TAT, i.e. OAC plus aspirin and P2Y12 inhibitor) to prevent ischemic complications. However, TAT doubles or even triples the risk of major bleeding complications. More recently, several clinical studies demonstrated that omitting aspirin, a strategy known as dual antithrombotic therapy (DAT) is safer compared to TAT with comparable efficacy.\n\nHowever, pooled evidence from recent meta-analyses suggests that patients treated with DAT are at increased risk of MI and ST. Insights from the AUGUSTUS trial showed that aspirin added to OAC and clopidogrel for 30 days, but not thereafter, resulted in fewer severe ischemic events. This finding emphasizes the relevance of early aspirin administration on ischemic benefit, also reflected in the current ESC guideline. However, because we consider the bleeding risk of TAT unacceptably high, we propose to use a short course of DAPT (omitting OAC for 1 month). There is evidence from the BRIDGE study that a short period of omitting OAC is safe in patients with AF. In this study, these patients are treated with DAPT, which also prevents stroke, albeit not as effective as OAC. This temporary interruption of OAC will allow aspirin treatment in the first month post-PCI where the risk of both bleeding and stent thrombosis is greatest.\n\nThe WOEST 3 trial is a multicentre, open-label, randomised controlled trial investigating the safety and efficacy of one month DAPT compared to guideline-directed therapy consisting of OAC and P2Y12 inhibitor combined with aspirin up to 30 days. We hypothesise that the use of short course DAPT is superior in bleeding and non-inferior in preventing ischemic events. The primary safety endpoint is major or clinically relevant non-major bleeding as defined by the ISTH at 6 weeks after PCI. The primary efficacy endpoint is a composite of all-cause death, myocardial infarction, stroke, systemic embolism, or stent thrombosis at 6 weeks after PCI.",[25,67,256,257,28,27,258,259,260,261,135],"Atrial Fibrillation","Atrial Flutter","Bleeding","Stroke","Stent Thrombosis","Embolism",[25,67,256,257,28,27,263,264,265,266,267,268,269,258,270,259,260,271,272,273],"Oral Anticoagulant","NOAC - Novel Oral Anticoagulant","DOAC - Direct Oral Anticoagulant","DAPT - Dual Antiplatelet Therapy","Antithrombotic Therapy","Dual Therapy","Triple Therapy","Thrombosis","Systemic Embolism","Percutaneous coronary intervention","Coronary artery disease","2023-12-14",{"date":276,"type":42},"2023-12-15",{"date":278,"type":42},"2023-01-11",{"date":280,"type":21},"2027-12-01",{"name":282,"class":89},"St. Antonius Hospital",20]